In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.

Latest From John Davis

Pipeline Watch: Phase III Starts In COVID-19, Bladder Cancer, Demodex Blepharitis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Readouts In CLL, Prostate Cancer, Conjunctivitis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Sanofi Spotlights Nirsevimab In RSV, Further Dupixent Development

Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.

Immune Disorders Clinical Trials

COVID-19 Boosts Sanofi's Ageing Lovenox Franchise, But Holds Back Travel Vaccine Sales

The COVID-19 pandemic led to a marked increase in sales of Sanofi’s LMW heparin, Lovenox, in the first quarter of 2021. The big pharma is also nearing late-stage clinical studies with two COVID-19 vaccine candidates.

Sales & Earnings Coronavirus COVID-19

Pipeline Watch: Phase III Starts In CLL, Urothelial Cancer, And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

ITM Charts A Path From Radionuclides To Radiotherapeutics And Attracts Financing

Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.

Cancer Financing
See All
UsernamePublicRestriction

Register